Our world-renowned Columbia and Weill Cornell Medicine physicians and surgeons in our comprehensive cardiology, heart surgery, and vascular programs spearhead groundbreaking clinical and scientific research and provide the most innovative treatments to optimize patient outcomes for all stages of disease complexity. Our clinicians are experts in minimally invasive approaches and novel therapeutics for all types of heart disease and work across disciplines to provide compassionate care to all patients.
Featured Updates
Results from a new multi-center study, led by oncologists at NewYork-Presbyterian and Weill Cornell Medicine, has described for the first time a key biomarker – absolute lymphocyte count (ALC) – that has the potential to predict therapeutic response to chimeric antigen receptor (CAR) T-cell immunotherapy for patients with relapsed/refractory multiple myeloma. While this FDA-approved treatment is widely used, until now there has not been a way to predict whether B-cell maturation antigen (BCMA) CAR T-cell therapy would elicit a good response.
The Latest
Pediatric Neurology & Neurosurgery
Crossing Specialty Lines for Rare Genetic Neurocutaneous Conditions
